Log in

Novartis Stock Price, Forecast & Analysis (VTX:NOVN)

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume11.21 million shs
Average Volume5.98 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+41-61-3241111

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees47
Next Earnings DateN/A
OptionableNot Optionable

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.


Novartis (VTX:NOVN) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the VTX under the ticker symbol "NOVN."

What price target have analysts set for NOVN?

11 equities research analysts have issued 1-year price objectives for Novartis' shares. Their forecasts range from CHF 80 to CHF 105. On average, they expect Novartis' stock price to reach CHF 91 in the next year. View Analyst Price Targets for Novartis.

What is the consensus analysts' recommendation for Novartis?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Has Novartis been receiving favorable news coverage?

News headlines about NOVN stock have trended very negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novartis earned a coverage optimism score of -3.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Novartis.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Novartis (NVS), Iamgold (IAG), General Motors (GM), DigitalGlobe (DGI), NovaGold Resources (NG), Walt Disney (DIS), Roche Holding Ltd. Genussscheine (ROG), AstraZeneca (AZN), Cyberark Software (CYBR) and Micron Technology (MU).

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Mr. G. Kelly Martin, CEO & Director (Age 60)
  • Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)
  • Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)
  • Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)
  • Dr. Carri Geer, Sr. VP & CTO

What is Novartis' official website?

The official website for Novartis is http://www.novartis.com/.

How can I contact Novartis?

Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.


MarketBeat Community Rating for Novartis (VTX NOVN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel